1. Home
  2. LILA vs NTLA Comparison

LILA vs NTLA Comparison

Compare LILA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd.

LILA

Liberty Latin America Ltd.

HOLD

Current Price

$8.05

Market Cap

1.5B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.89

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LILA
NTLA
Founded
2017
2014
Country
Bermuda
United States
Employees
10000
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
LILA
NTLA
Price
$8.05
$12.89
Analyst Decision
Buy
Buy
Analyst Count
2
18
Target Price
$9.75
$18.34
AVG Volume (30 Days)
367.1K
4.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.14
EPS
N/A
N/A
Revenue
N/A
$57,877,000.00
Revenue This Year
N/A
$1.71
Revenue Next Year
$7.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
59.55
52 Week Low
$4.25
$5.90
52 Week High
$9.04
$28.24

Technical Indicators

Market Signals
Indicator
LILA
NTLA
Relative Strength Index (RSI) 57.08 54.55
Support Level $7.90 $10.44
Resistance Level $8.25 $14.61
Average True Range (ATR) 0.39 0.85
MACD 0.01 -0.05
Stochastic Oscillator 53.74 68.14

Price Performance

Historical Comparison
LILA
NTLA

About LILA Liberty Latin America Ltd.

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: